Impact on Inflammation and Recovery of Skin Barrier by Nordihydroguaiaretic Acid as a Protease-Activated Receptor 2 Antagonist

Hyo Young Kim¹, Jung Hyun Goo¹, Yeon Ah Joo¹, Ha Yoen Lee¹, Se Mi Lee¹, Chang Taek Oh¹, Soo Mi Ahn¹, Nam-Hoon Kim² and Jae Sung Hwang¹,*

¹Department of Genetic Engineering, College of Life Science and Skin Biotechnology Center, Kyung Hee University, Yongin 446-701, ²Sehwa High School, Seoul 137-049, Republic of Korea

Abstract

Atopic dermatitis is a chronic, inflammatory disease of the skin with increased transepidermal water loss. Both an abnormal inflammatory response and a defective skin barrier are known to be involved in the pathogenesis of atopic dermatitis. Protease activated receptor 2 (PAR2) belongs to a family of G-protein coupled receptors and is activated by both trypsin and a specific agonist peptide, SLIGKV-NH₂. PAR2 is expressed in suprabasal layers of the epidermis and regulates inflammatory responses and barrier homeostasis. In this study, we show that nordihydroguaiaretic acid (NDGA) inhibits the PAR2-mediated signal pathway and plays a role in skin barrier recovery in atopic dermatitis. Specifically, NDGA reduces the mobilization of intracellular Ca²⁺ in HaCaT keratinocytes by down-regulating inflammatory mediators, such as interleukin-8, thymus and activation-regulated chemokine and intercellular cell adhesion molecule-1 in HaCaT keratinocytes. Also, NDGA decreases the protein expression of involucrin, a differentiation maker of keratinocyte, in both HaCaT keratinocytes and normal human epidermal keratinocytes. We examined NDGA-recovered skin barrier in atopic dermatitis by using an oxazolone-induced atopic dermatitis model in hairless mice. Topical application of NDGA produced an increase in transepidermal water loss recovery and a decrease in serum IgE level, without weight loss. Accordingly, we suggest that NDGA acts as a PAR2 antagonist and may be a possible therapeutic agent for atopic dermatitis.

Key Words: Protease activated receptor 2, Atopic dermatitis, Skin barrier, Nordihydroguaiaretic acid, PAR2 antagonist

INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by erythema, eruption, pruritus and hyperkeratosis accompanied with increased transepidermal water loss (TEWL) (Tsujii et al., 2009). AD has a complex etiology that involves abnormal immunological and inflammatory pathways that yield defective skin barrier, exposure to environmental agents, and neuropsychological factors (Jin et al., 2009). Epidermal barrier disruption increases the invasion of allergens and bacteria and worsens the inflammatory response. The epidermal barrier is developed when keratinocytes differentiate and secrete lamellar bodies.

Protease activated receptor 2 (PAR2) belongs to a subfamily of G protein-coupled receptors (Bohm et al., 1996) and is activated through proteolytic cleavage by specific serine proteases, such as mast cell tryptase and trypsin. These serine proteases cleave the extracellular N-terminal peptide in humans. Subsequently, the cleaved peptide sequence, as a tethered ligand, activates the receptor, itself (Vergnolle et al., 1999). In skin, PAR2 is expressed in suprabasal layers of epidermis (Nystedt et al., 1996). PAR2 expression is associated with the regulation of keratinocyte proliferation and differentiation, maintenance of the epidermal barrier and inflammation (Frateschi et al., 2011).

Skin barrier disruption increases the pH in the epidermis and subsequently increases activity of serine proteases (Hachem et al., 2006; Demerjian et al., 2008). PAR2 activation by a specific activating peptide was shown to delay barrier recovery, accelerate cornification and inhibit lamellar body (LB) secretion after tape-stripping in hairless mice (Hachem et al., 2006; Jeong et al., 2008). In another mouse model, acute barrier disruption caused terminal differentiation of keratinocytes in conjunction with caspase-14, and this differentiation was
decreased by treatment with serine protease inhibitors (Demerjian et al., 2008). This event was shown to be regulated by PAR2-derived cytoskeletal and plasma membrane dynamics (Roelant et al., 2011). In PAR2−/− mice, after tape-stripping, the skin barrier recovered with enhanced LB secretion (Hacem et al., 2006; Jeong et al., 2008; Roelant et al., 2011). Also the transgenic mice, Grhl3ΔAKR, displayed increased expression of PAR2 and exhibited phenotypes characterized by scaly skin, hyperelastic epidermis and scratching behavior (Frateschi et al., 2011).

PAR2 is also correlated with inflammatory responses. PAR2 activation increased the secretion of IL-8, NF-κB-dependent intercellular cell adhesion molecule-1 (ICAM-1) and prosta
glandin E2 (PGE2) (Hou et al., 1998, Vergnolle et al., 1998, Buddenkotter et al., 2005).

We examined the effect of NDGA as a PAR2 antagonist on the recovery of skin barrier in atopic dermatitis. NDGA is a natural herbal antioxidant found in the creosote bush, Larrea tridentate (He et al., 2004). NDGA is well known as a lipoygenase inhibitor and anti-tumor agent (Eads et al., 2009; Mahajan et al., 2011; Rahman et al., 2011). Notably, NDGA inhibits the intracellular Ca2+ influx after treatment with trypsin or PAR2-activating peptide (SLIGKV-NH2). In an oxazolone-in
duced atopic dermatitis model using hairless mice, we studied whether NDGA affects keratinocyte differentiation and inflammation by inhibiting PAR2 activation.

**MATERIALS AND METHODS**

**Cell culture**

Immortalized human keratinocyte cell line, HaCaT, cells were purchased from Amore Pacific (Korea). The cells were generally cultured in high glucose DMEM with FBS 10%, 100 units/ml of penicillin and 100 µg/ml of streptomycin (WelGENE Inc., Korea). Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air.

Normal human epidermal keratinocytes (NHEKs) from neonatal origin were purchased from Invitrogen (USA). The NHEKs were used until passage number 5. The cells were cultured in Epilife® medium with 60 µM calcium and human keratinocyte growth supplement (Invitrogen, USA) and incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air.

**Measurement of intracellular Ca2+**

HaCaT cells were seeded on a 96-well plate (black wells and clear bottoms, Greiner bio-one, Germany) at 4×10^4 cells/well. After 24 hours, media were changed with 2 µM Fluo-4, AM (Invitrogen, USA), 0.02% Pluronic® F-127 (Invitrogen, USA) and 2.5 mM Probenecid (Sigma, USA) in Hank’s balanced salt solution (HBSS, Sigma, USA) containing 20 mM HEPES (Sigma, USA) for 30 minutes at 37°C and protected from light. The cells were stabilized for 15 minutes at room temperature during shaking. Then, NDGA (Sigma, USA) were pretreated before activation of PAR2. After 30 minutes, 20 µM of PAR2-activating peptide (SLIGKV-NH2, Bachem, Switzerland) or 2 unit/ml of trypsin (Sigma, USA) was added with Flexstation 3 (Molecular Devices, USA), and intracellular Ca2+ was simultaneously measured using an excitation wavelength of 485 nm and an emission wavelength of 525 nm at room temperature. The data were analyzed with SoftMax® Pro (Molecular Devices, USA), and the mobilization of intracellular Ca2+ was calculated as the minimum value subtracted from the maximum value.

**Measurement of secreted IL-8 chemokine**

HaCaT cells were seeded on 96-well plate at 4×10^4 cells/well. After 24 hours, cells were starved with DMEM without FBS for 12 hours. NDGA were pretreated for 30 minutes. Then, 100 µM of SLIGKV-NH2 was added and cultured for 24 hours. Supernatants were harvested and analyzed with Humain CXCCL8/IL-8 DuoSet kit (R&D Systems, USA). Absorbance was measured at 450 nm and corrected at 540 nm using Infinite® M200 (TECAN, Switzerland).

**Measurement of TARC level**

HaCaT cells were seeded on a 96-well plate at 3×10^4 cells/well. After 24 hours, cells were starved using DMEM without FBS for 12 hours. Inflammatory responses were induced by treating with both INF-γ and TNF-α (ProSpec protein specialists, Korea) at 10 ng/ml for 24 hours. Then, NDGA was introduced for 72 hours. Dexamethasone (Sigma, USA) the positive control was also treated with 100 µg/ml. Supernatants were harvested and analyzed with Quantikine® Human CCL17/TARC immunoassay kit (R&D systems, USA). Absorbance was measured at 450 nm and corrected at 540 nm using Infinite® M200.

**Western blot**

The cells were treated with ice-cold lysis buffer, consisting of RIPA solution (Noble Bio, Korea), protease inhibitor cocktail (Sigma, USA) and 1 mM phenylmelenesulfonlfy fluoride (PMSF, Sigma, USA) for 60 minutes. The lysates were sonicated and centrifuged at 13,000 × g and 4°C for 20 minutes. Then, supernatants were harvested and protein concentration was normalized. The protein samples were stored at -20°C. The samples were mixed with LDS sample buffer and sample reducing buffer (Invitrogen, USA) and boiled at 95°C for 5 minutes. The reduced samples were loaded on NuPAGE® 10% Bis-Tris gel and run with MOPS SDS running buffer (Invitrogen, USA). Then, the proteins were transferred to polyvi
ylidene fluoride transfer membrane (PVDF membrane, PALL corporation, USA). The membrane was blocked with 5% skim milk in TBS-T buffer (0.1% Tween® 20, 100 mM NaCl and 10 mM Tris-HCl, pH 7.5) and then probed using mouse monoclonal anti-involucrin antibody (1/1,000, Abcam, UK), sheep polyclonal anti-ICAM-1 antibody (1/1,000, R&D Systems, USA), mouse monoclonal anti-β-actin antibody (1/10,000, Sigma, USA), donkey anti-sheep IgG antibody (1/5,000, Bethyl Laboratories, Inc., USA) and goat anti-mouse IgG antibody (1/10,000, Bio-Rad, USA). Bands were detected with WEST-ZOL® plus Western Blot Detection system (NIRON Biotechnology, Korea) and visualized with G : Box chemi (SYNGENE, USA). Densitometric analysis was performed using Image J software. The band density was normalized with β-actin intensity.

**Animal study**

Female hairless mice (SKH-1), aged 6-11 weeks old, were purchased from HOSHINO laboratory animals (Japan) and fed mouse diet and water ad libitum. All animal procedures were approved by the Institutional Animal Care and Use Committees of Gyeonggi Bio Center and performed in accordance with their guidelines. The following procedures made refer-
ence to those used by Man et al., 2008. All animals were sensitized with a single topical application of 10% oxazolone (100 μl/mouse) to the dorsal region except for the normal healthy mice group. To induce atopic dermatitis, 150 μl oxazolone 0.5% was topically applied with acetone: olive oil in a 4:1 (v/v) ratio twice daily for 9 days. After 1 day, TEWL was measured using VapoMeter (Delfin Technologies, Inc., USA). The mice were regrouped using TEWL levels. Then, 100 μl NDGA was applied with vehicle (propylene glycol: ethanol: water in a 5:3:2 (v/v/v) ratio) twice daily for an additional 5 weeks. Then one hour after NDGA application, oxazolone 0.5% was applied once daily. Dexamethasone 0.05% was used as positive control. TEWL was measured before and after (Day 0) oxazolone-induced atopic dermatitis and during NDGA treatment (Days 10, 22, and 26). Recovery of TEWL was analyzed with following formula: \[ \frac{1}{2} \times (\text{TEWL of normal group} \times \text{at indicated time}) - \text{TEWL after inducing atopic dermatitis} \] average TEWL of normal group at indicated time. TEWL data were measured four times at each mouse and the TEWL average of each mouse was used as a sample.

**Measurement of serum IgE level**

Retro orbital sinus blood samples were collected with Mini-Collect® Tube (Greiner Bio-One, Austria) before and after oxazolone-induced atopic dermatitis and again on the final day (Day 27). Collected blood samples were kept at room temperature for over 30 minutes to clot. The samples were centrifuged at 4°C and 10,000 rpm for 10 minutes. Then, supernatants were stored at -80°C. Serum IgE concentration was diluted 1/40 with reagent diluent buffer and determined with Mouse IgE ELISA Quantitation kit (Bethyl Laboratories, Inc., USA) following instructions provided by the manufacturer. Absorbance was measured at 450 nm and corrected at 540 nm using Infinite® M200.

**Statistics**

All data are given as mean ± SEM. Statistical analyses for in vitro studies were performed by t-test using Excel (Microsoft, USA). The data of animal study were analyzed by one-way analysis of variance (ANOVA, SPSS, Inc., USA) followed by post hoc Duncan’s multiple range test to compare differences among groups. Significance was defined as \( p \)-value <0.05.

**RESULTS**

**NDGA inhibited PAR2-induced intracellular Ca\(^{2+}\) influx in keratinocytes**

PAR2 activation induces intracellular Ca\(^{2+}\) mobilization. HaCaT keratinocytes were treated with SLIGKV-NH\(_2\) or trypsin to induce PAR2 activation, followed by several concentrations of NDGA treatment in order to induce changes in intracellular Ca\(^{2+}\) concentration. The chemical structure of NDGA is shown in Fig. 1. NDGA led to decreased SLIGKV-NH\(_2\) (20 μM) and trypsin (20 μM) induced intracellular Ca\(^{2+}\) mobilization in a dose-dependent manner (Fig. 2). 6.25 μM, 12.5 μM, 25 μM and 50 μM of NDGA treatment inhibited intracellular Ca\(^{2+}\) mobilization in HaCaT keratinocytes by 22%, 42%, 79% and 92% respectively when stimulated by SLIGKV-NH\(_2\). and by 24%, 45%, 80% and 98% respectively when stimulated by trypsin relative to DMSO control (Fig. 2B). Calcium signals generated by HaCaT keratinocytes through release of Ca\(^{2+}\) were significantly reduced by NDGA.

**NDGA decreased PAR2-induced inflammatory responses in keratinocytes**

PAR2 activation induces inflammatory responses. HaCaT keratinocytes were treated with SLIGKV-NH\(_2\) or TNF-α/IFN-γ to induce inflammatory responses. They were simultaneously exposed to various concentrations of NDGA. 100 μM of SLIGKV-NH\(_2\) raised the secretion of IL-8. NDGA was introduced at 1.25 μM, 2.5 μM, 5 μM, 10 μM and 20 μM. The secreted IL-8 level decreased significantly in a dose-dependent manner (Fig. 3A). 25 μM of SLIGKV-NH\(_2\) stimulated ICAM-1 expression, and 0.5 μM and 2 μM of NDGA inhibited ICAM-1 expression (Fig. 3C). Thymus and activation-regulated che-
mokine (TARC) was induced by exposure to TNF-α and IFN-γ at 10 ng/ml. 1.25 μM, 2.5 μM, 5 μM, 10 μM and 20 μM of NDGA decreased the secreted TARC level, though not statistically significantly, in a dose-dependent manner (Fig. 3B). Dexamethasone (steroid) was used as positive control and decreased TARC level significantly at 250 μM.

NDGA inhibited PAR2-induced terminal differentiation in keratinocytes

PAR2 activation induced terminal differentiation of keratinocytes. In differentiating keratinocytes, many proteins such as involucrin, loricrin and filaggrin are upregulated (Steven and Steinert, 1994). We investigated whether NDGA decreased involucrin protein expression by inhibiting PAR2 activation in HaCaT keratinocytes and NHEKs. In HaCaT keratinocytes, treatment with 100 μM SLIGKV-NH₂ for 72 hours showed a 3.1-fold increase in involucrin expression compared with control. NDGA exposure at 0.5 μM, 2 μM and 10 μM inhibited involucrin expression by 1.3-, 0.3- and 0.9-fold, respectively, compared with treatment of SLIGKV-NH₂ alone (Fig. 4A).

In NHEKs, 100 μM of SLIGKV-NH₂ was introduced for 120 hours and upregulated involucrin protein level 1.4-fold. SLIGKV-NH₂ was treated with 0.01 μM, 0.05 μM and 0.2 μM of NDGA and all doses except 0.01 μM dose-dependently down-regulated the involucrin expression (Fig. 4B).

NDGA effects on oxazolone-induced atopic dermatitis in hairless mice

To investigate whether NDGA could recover skin barrier in atopic dermatitis in vivo, we induced atopic dermatitis in hairless mice using oxazolone 0.5% topically to dorsal skin for 9 days, followed by NDGA. Skin barrier recovery was checked by dorsal TEWL change. Dexamethasone 0.05% was used as a positive control. At 10 days after NDGA treatment (0.01%, 0.1% and 1%), skin barrier was recovered at 18%, 26% and 7% respectively, while vehicle treatment scarcely affect
Kim et al. Recovery of Skin Barrier and Inflammation by NDGA

The barrier recovery. The dexamethasone-treated group experienced 50% recovery at day 10. At day 16, treatment of NDGA (0.1% and 1%) recovered more than the vehicle, but the 0.01% concentration did not yield significant results. After 22 days, the dexamethasone-treated group had recovered almost 81% of the skin barrier, and other groups had recovered about 65% (Fig. 5A).

Serum IgE levels at basal condition were almost zero. Oxazolone treatment increased serum IgE level to approximately 500 ng/ml. Dexamethasone and NDGA-treated groups showed reduced serum IgE levels at day 27. IgE levels in the vehicle-treated group decreased 15%, levels in the dexamethasone (0.05%) and NDGA (0.01%, 0.1% and 1%) groups decreased by 25%, 22%, 5% and 24%, respectively (Fig. 5B).

Dexamethasone side effects include weight loss and skin thinning. In this study, the dexamethasone-treated group displayed a significant decrease in weight at days 10 and 26 compared with the vehicle-treated group (Fig. 5C).

**DISCUSSION**

AD is a chronic inflammatory skin disease which occurs mainly in childhood and is a pervasive health problem in developed countries (Kang et al., 2008). Both abnormal inflammatory response and defective skin barrier are characteristic of AD (Jin et al., 2009). Barrier disruption increases the invasion of allergens, such as dust mite waste, pollen and pet dander and causes more severe inflammation (Elias and Steinhoff, 2008). This cycle comprises the “outside-inside-outside” model of AD pathogenesis (Elias and Steinhoff, 2008). PAR2 correlates with inflammatory responses and differentiation of keratinocytes. The proliferation and differentiation of keratinocytes in the epidermis control barrier permeability and homeostasis. The aim of this study is to find a new PAR2 antagonist to interfering with PAR2 activation, and consequently to halt symptoms of atopic dermatitis. Serine protease inhibitors, such as aprotinin and t-AMCHA, are known for inhibiting PAR2 activation by blocking cleavage of the N-terminus and subsequent inhibition of PAR2-activating peptide (He et al., 2004). We found that NDGA decreased intracellular Ca++ mobilization induced by SLIGKV-NH2 and trypsin in HaCaT keratinocytes (Fig. 2). Our results indirectly indicated that PAR2 activation can be specifically inhibited by NDGA. Consequently, we have shown that NDGA inhibits PAR2-induced inflammation and keratinocyte differentiation.

PAR2 activation is known to increase the secretion of IL-8 and NF-κB-dependent ICAM-1 expression (Hou et al., 1998; Vergnolle et al., 1998). Additionally, PAR2 activation stimulates the mRNA expression of IL-1α, IL-8, TNF-α and human beta defensin (hBD)-2 in keratinocytes (Lee et al., 2010). Recent studies have also revealed the importance of PAR2 in itching and pain sensations. In rat and mouse DRG neurons, PAR2 was shown to be associated with long-lasting thermal and mechanical hyperalgesia by mediating the transient receptor potential vanilloid 4 ion channel (Grant et al., 2007; Jeong et al., 2008). We showed that NDGA inhibited PAR2-induced inflammation. SLIGKV-NH2 treatment increased IL-8 and ICAM-1 expression in HaCaT keratinocytes. NDGA treatment decreased IL-8 and ICAM-1 expression in a dose-dependent manner. Also, NDGA treatment decreased TARC secretion induced by TNF-α and IFN-γ in HaCaT keratinocytes (Fig. 3).
PAR2 activation induces the abnormal differentiation of keratinocytes. In previous studies, epidermal barrier disruption by repetitive tape-stripping caused a pH rise and an increase in serine protease activity. Serine protease was shown to cleave the PAR2 N-terminus, activating PAR2. PAR2 activation induced abnormal differentiation by stimulating cornification and inhibiting lamellar body secretion, thus delaying barrier recovery (Hachem et al., 2006, Demerjian et al., 2008; Jeong et al., 2008). To confirm the effects of NDGA on keratinocyte differentiation, we examined the expression of involucrin in HaCaT keratinocytes and NHEKs. NDGA decreased the expression of involucrin induced by SLIGKV-NH2 in both HaCaT keratinocytes and NHEKs (Fig. 4).

To determine the effects of NDGA on atopic dermatitis, we used an oxazolone-induced atopic dermatitis model. Oxazolone-induced atopic dermatitis was checked by measuring TEWL. Basal TEWL was about 20 g/m², and after AD induction TEWL was over 70 g/m². Topical treatment of NDGA decreased TEWL, and NDGA had the best effect on barrier recovery at day 10 (Fig. 5A). Also treatment with NDGA at concentrations of 0.01% and 1% reduced serum IgE level by 22%, 5% and 24%, respectively, compared with vehicle at day 27 (Fig. 5B). From these results, we concluded that NDGA could affect barrier recovery in atopic dermatitis without inducing weight loss.

In summary, NDGA blocked the PAR2-mediated signal pathway and promoted skin barrier recovery in atopic dermatitis. Our results suggest that NDGA is a PAR2 antagonist and may be a potential therapeutic agent for atopic dermatitis. For further study, we recommend examining the effects of NDGA on atopic dermatitis by using NC/Nga mice, a mice strain that spontaneously develops atopic dermatitis.

ACKNOWLEDGMENTS

This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant No.: A103017).

REFERENCE


Steven, A. C. and Steinert, P. M. (1994) Protein composition of cor-


